A phase IA dose-escalation study of PHI-101, a new checkpoint kinase 2 inhibitor, for platinum-resistant recurrent ovarian cancer - Concepedia

Concepedia

Publication | Open Access

A phase IA dose-escalation study of PHI-101, a new checkpoint kinase 2 inhibitor, for platinum-resistant recurrent ovarian cancer

DOI Full Paper Access

28

Citations

10

References

2022

Year

Soo Jin Park, Suk‐Joon Chang, Dong Hoon Suh, Tae‐Wook Kong, Heekyoung Song, Tae Hun Kim, Jae‐Weon Kim, Hee Seung Kim, Sung Jong Lee

References

	Year	Citations

Page 1